Terbinafine‐induced hepatic failure requiring liver transplantation | Zendy

Perveze Zeeshan | Zendy; Johnson Mark W. | Zendy; Rubin Raymond A. | Zendy; Sellers Marty | Zendy; Zayas Carlos | Zendy; Jones Jody L. | Zendy; Cross Rosemary | Zendy; Thomas Kimberly | Zendy; Butler Bradley | Zendy; Shrestha Roshan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Terbinafine‐induced hepatic failure requiring liver transplantation

Author(s) -

Perveze Zeeshan,

Johnson Mark W.,

Rubin Raymond A.,

Sellers Marty,

Zayas Carlos,

Jones Jody L.,

Cross Rosemary,

Thomas Kimberly,

Butler Bradley,

Shrestha Roshan

Publication year - 2007

Publication title -

liver transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.814

H-Index - 150

eISSN - 1527-6473

pISSN - 1527-6465

DOI - 10.1002/lt.21034

Subject(s) - medicine , liver transplantation , fulminant hepatic failure , liver injury , acetaminophen , liver disease , chronic liver disease , liver failure , terbinafine , gastroenterology , transplantation , pharmacology , cirrhosis , antifungal , dermatology , itraconazole

Drug‐induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%‐20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular‐cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine‐induced severe liver failure requiring liver transplantation. Liver Transpl 13:162–164, 2007. © 2006 AASLD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research